Through an in-depth review of patient charts, details such as product dosing and titration, switching, concomitant medications and a host of laboratory and patient demographic variables help define…
The treatment armamentarium for chronic myelogenous leukemia (CML) in Brazil and Mexico includes all three currently marketed tyrosine kinase inhibitors (TKIs): Glivec (imatinib,Novartis) for newly…
What Do Physicians and U.S. Payers Expect from the First-to-Market Therapies Targeting Geographic Atrophy? Geographic atrophy (GA) is the advanced dry form of age-related macular degeneration (AMD…
In Europe, multiple myeloma (MM) treatment is centered on the use of three major agents—Janssen’s Velcade (bortezomib), Celgene’s Revlimid (lenalidomide), and Celgene’s Thalidomide (…
Warfarin has been the mainstay of anticoagulation therapy for the past several decades, but difficulties associated with its use and the clinical management of patients have prompted the…
Oncologists Are Eager for Therapies Extending Overall Survival Ovarian cancer (CaO) ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female…
Changes in U.S. policy have accelerated the implementation and use of electronic health records (EHRs) in the practice, disrupting physician workflow and decision making. In the meanwhile, reliance…
Oncologists Are Eager for Therapies Extending Overall Survival Ovarian cancer (CaO) ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female…
What Do Physicians and U.S. Payers Expect from the First-to-Market Therapies Targeting Geographic Atrophy? Geographic atrophy (GA) is the advanced dry form of age-related macular degeneration (AMD…
Last Updated 22 May 2014 Although colectomy is curative for the potentially fatal immune disease ulcerative colitis (UC), this procedure is life altering, and therefore unmet need remains for…
With Few Good Treatment Choices, Which Emerging Therapies Hold the Greatest Potential for Managing AML and What Types of Therapies Will Receive Reimbursement? Despite the introduction and use of…
As Abiraterone and Enzalutamide Gain Traction in the Market, What Key Attributes Do Oncologists and Payers Say Will Differentiate Emerging Therapies? The first-line (chemotherapy-naive) metastatic…
With Few Good Treatment Choices, Which Emerging Therapies Hold the Greatest Potential for Managing AML and What Types of Therapies Will Receive Reimbursement? Despite the introduction and use of…
Improved patient access to specialized medical care and increased use of target therapies in oncology are expanding the multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL) markets in Brazil…
As Abiraterone and Enzalutamide Gain Traction in the Market, What Key Attributes Do Oncologists and Payers Say Will Differentiate Emerging Therapies? The first-line (chemotherapy-naive) metastatic…